Overview

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Collaborator:
H. Lundbeck A/S
Treatments:
Vortioxetine